<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366438">
  <stage>Registered</stage>
  <submitdate>30/05/2014</submitdate>
  <approvaldate>11/06/2014</approvaldate>
  <actrnumber>ACTRN12614000622606</actrnumber>
  <trial_identification>
    <studytitle>Pilot Trial Proposal looking at the use of Cannabinoids for analgesia in chronic myocardial ischaemic chest pain, using Sativex Oromucosal Spray</studytitle>
    <scientifictitle>In a patient with chronic ischaemic chest pain, will Sativex Oromucosal Spray reduce their pain</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Ischaemic Chest Pain</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>In this initial trial the treatment group will be patients admitted to Waikato Hospital Emergency Department or Cardiology department, who are known to suffer from intractable coronary disease. 
They will score their pain from 1-10 on a Numeric Rating Scale (NRS) and be given a single oromucosal spray dose of Sativex up to every 4 hours for a max of 5 days their NRS pain score will then be recorded one hour after receiving the dose.

Each 100 microlitre Sativex spray contains:

2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD).

Each ml contains:

38-44 mg and 35-42 mg of two extracts (as soft extracts) from Cannabis sativa L., folium cum flore (Cannabis leaf and flower) corresponding to 27 mg delta-9-tetrahydrocannabinol and 25 mg cannabidiol.

Extraction solvent: Liquid carbon dioxide.

Excipient(s) with known effect: each 100 microlitre spray also contains up to 0.04 g ethanol.</interventions>
    <comparator>No control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Chest pain. using a 10 point Numeric Rating Scale NRS. The patients will be asked to give a score proir to administation of the spray and 1 hour afterwards.</outcome>
      <timepoint>Outcome is assessed one hour after administration of every spray received over the 5 day intervention period or until pain is relieved completely.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>In this initial trial the treatment group will be patients admitted to Waikato Hospital Emergency Department or Cardiology department, who are known to suffer from intractable coronary disease</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>	Hypersensitivity to cannabinoids
	History of Schizophrenia
	Pregnant or breast feeding mothers</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>1/07/2014</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Waikato</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Adrian Owen</primarysponsorname>
    <primarysponsoraddress>Waikato Hospital
Pembroke Street
Private Bag 3200
Hamilton 3240
NEW ZEALAND

</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Currently treatment for patients with longstanding chest pain caused by blockage of the blood supply to the heart is often ineffective.

This trial will be to see if a spray under the tongue of a cannabis extract will help to relieve their pain. It is already used for chronic pain associated with cancer.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>HDEC</ethicname>
      <ethicaddress>Health and Disability Ethics Committees
C/- MEDSAFE, Level 6, Deloitte House
10 Brandon Street
PO Box 5013
Wellington
6145</ethicaddress>
      <ethicapprovaldate />
      <hrec>NZ/1/E69504</hrec>
      <ethicsubmitdate>17/06/2014</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/366438-Ethics form.pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/366438-Trial_proposal_2[1].doc</filepath>
  </attachment>
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Adrian Owen</name>
      <address>Waikato Hospital
Pembroke Street
Private Bag 3200
Hamilton 3240
NEW ZEALAND

</address>
      <phone>+6421803229</phone>
      <fax />
      <email>adrianowen@live.com</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Adrian Owen</name>
      <address>Waikato Hospital
Pembroke Street
Private Bag 3200
Hamilton 3240
NEW ZEALAND

</address>
      <phone>6421803229</phone>
      <fax />
      <email>adrianowen@live.com</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Adrian Owen</name>
      <address>Waikato Hospital
Pembroke Street
Private Bag 3200
Hamilton 3240
NEW ZEALAND

</address>
      <phone>6421803229</phone>
      <fax />
      <email>adrianowen@live.com</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>